BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21875504)

  • 1. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
    Ram R; Storer B; Mielcarek M; Sandmaier BM; Maloney DG; Martin PJ; Flowers ME; Chua BK; Rotta M; Storb R
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):414-22. PubMed ID: 21875504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.
    Inamoto Y; Flowers ME; Appelbaum FR; Carpenter PA; Deeg HJ; Furlong T; Kiem HP; Mielcarek M; Nash RA; Storb RF; Witherspoon RP; Storer BE; Martin PJ
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1088-92. PubMed ID: 21421070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Luznik L; Pasquini MC; Logan B; Soiffer RJ; Wu J; Devine SM; Geller N; Giralt S; Heslop HE; Horowitz MM; Jones RJ; Litzow MR; Mendizabal A; Muffly L; Nemecek ER; O'Donnell L; O'Reilly RJ; Palencia R; Schetelig J; Shune L; Solomon SR; Vasu S; Ho VT; Perales MA
    J Clin Oncol; 2022 Feb; 40(4):356-368. PubMed ID: 34855460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
    de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
    PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Rotta M; Storer BE; Storb R; Martin PJ; Flowers ME; Vernon MS; Peffer A; Maloney DG; Deeg HJ; Sandmaier BM; Appelbaum FR; Mielcarek M
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1463-6. PubMed ID: 20685260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
    Puckrin R; Kwan ACF; Blosser N; Leyshon C; Duggan P; Daly A; Zepeda V; Stewart D; Chaudhry A; Storek J; Jamani K
    Cytotherapy; 2023 Oct; 25(10):1101-1106. PubMed ID: 37306643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
    Watkins B; Qayed M; McCracken C; Bratrude B; Betz K; Suessmuth Y; Yu A; Sinclair S; Furlan S; Bosinger S; Tkachev V; Rhodes J; Tumlin AG; Narayan A; Cribbin K; Gillespie S; Gooley TA; Pasquini MC; Hebert K; Kapoor U; Rogatko A; Tighiouart M; Kim S; Bresee C; Choi SW; Davis J; Duncan C; Giller R; Grimley M; Harris AC; Jacobsohn D; Lalefar N; Norkin M; Farhadfar N; Pulsipher MA; Shenoy S; Petrovic A; Schultz KR; Yanik GA; Waller EK; Levine JE; Ferrara JL; Blazar BR; Langston A; Horan JT; Kean LS
    J Clin Oncol; 2021 Jun; 39(17):1865-1877. PubMed ID: 33449816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.
    Ueda Oshima M; Storer BE; Qiu H; Chauncey T; Asch J; Boyer MW; Giaccone L; Flowers M; Mielcarek M; Storb R; Maloney DG; Sandmaier BM
    Transplant Cell Ther; 2021 Feb; 27(2):163.e1-163.e7. PubMed ID: 33830025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
    Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Rashid N; Gooley T; Furlong T; Lee SJ; Martin PJ; Storb R; Mielcarek M
    Transplant Cell Ther; 2023 Nov; 29(11):701.e1-701.e8. PubMed ID: 37657769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis.
    Moiseev IS; Burmina EA; Muslimov AR; Pirogova OV; Bondarenko SN; Darskaya EI; Tarakanova YA; Senina NG; Afanasyev BV
    Ann Hematol; 2017 Jun; 96(6):935-942. PubMed ID: 28343273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation.
    Kubo H; Imataki O; Fukumoto T; Ishida T; Kubo YH; Yoshida S; Uemura M; Fujita H; Kadowaki N
    Cytotherapy; 2024 May; 26(5):472-481. PubMed ID: 38456854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
    Sala E; Neagoie AM; Lewerenz J; Saadati M; Benner A; Gantner A; Wais V; Döhner H; Bunjes D
    Transplant Cell Ther; 2024 Jun; 30(6):586.e1-586.e11. PubMed ID: 38508452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
    Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
    Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
    Parikh CR; Schrier RW; Storer B; Diaconescu R; Sorror ML; Maris MB; Maloney DG; McSweeney P; Storb R; Sandmaier BM
    Am J Kidney Dis; 2005 Mar; 45(3):502-9. PubMed ID: 15754272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.